Should you get a Life ... 360?

Published 11-JUN-2021 14:02 P.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

I was recently introduced to an app called Life360, which is designed for family and friends to share their location. One of the cool features of this app is that it allows family members to track how fast people are driving and to call for assistance if someone is in an accident.

While the app is free, it also has some additional features, which subscribers pay for. When I investigated this company, I found it was headquartered in San Francisco but it had listed on the Australian Securities Exchange (ASX) in May 2019.

During the IPO, it raised $112.7 million by issuing 23.5 million new chess depositary interests (CDIs) at $4.79 each, as CDIs allow a non-Australian company to list their shares on the ASX. The company began trading on 10 May 2019 but like most IPOs, it traded down in price and by 23 March 2020 it had fallen over 70 per cent to $1.51.

Over the last 12 months, however, Life360 has achieved 20 per cent revenue growth year on year despite COVID-19, which has seen its share price rise over 300 per cent to a new all-time high this week of $6.49 with many analysts promoting the stock as a strong buy.

While I like the look of this stock and believe it has the potential to rise further, I think most of the rise has already occurred, at least in the short term.

That said, over the longer-term this stock looks attractive, as it is in the technology sector and has a broad international client base paying monthly fees, so subscribers can have peace of mind not only knowing where their loved ones are but that they are safe, which means their likely to be very loyal long-term users.

Dale Gillham is Chief Analyst at Wealth Within and international bestselling author of How to Beat the Managed Funds by 20%. He is also the author of the award-winning book Accelerate Your Wealth—It’s Your Money, Your Choice, which is available in all good book stores and online at www.wealthwithin.com.au

NB: Neither Dale or Wealth Within are affiliated with any of our related portfolios.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X